Once a regional herbal remedy known mainly in parts of Southeast Asia, kratom has become a prominent topic in Western discussions about pain management, wellness and drug policy. The leaf of the tropical tree Mitragyna speciosa is now used by many people who say it helps them manage discomfort, support their mood and, in some cases, move away from stronger medications.
Public interest in kratom surged in the United States after a 2016 move by the Drug Enforcement Administration (DEA) to place its active compounds into the most restrictive federal schedule, a proposal that prompted a strong response from consumers and some researchers. While that emergency scheduling plan was later withdrawn, it highlighted an ongoing conversation: how to recognize kratom’s reported benefits while also ensuring products are manufactured and used in ways that support consumer safety, an approach echoed in federal overviews of the substance from agencies such as the National Institute on Drug Abuse and the U.S. Food and Drug Administration (FDA), which both provide detailed summaries of current evidence in accessible formats on their public websites at NIDA and FDA.
Kratom itself is a plant. Native to countries including Thailand, Malaysia and Indonesia, it belongs to the coffee family and has a long history of traditional use. In its regions of origin, people have commonly chewed fresh leaves or brewed them into teas to help manage everyday aches or maintain energy during long hours of manual labor. Today, kratom is typically sold as dried leaf powder, capsules or extracts, and is widely available online and in specialty shops, where it is often presented as a natural option for those exploring alternatives to conventional pain and mood treatments, a pattern described in both scientific reviews and summaries such as those hosted by Frontiers in Pharmacology and the NIDA overview.
Many modern users say kratom fills a space that they feel existing options have not fully addressed. Survey research discussed in Live Science’s article “5 Things to Know About Kratom” found that people with chronic pain frequently reported meaningful relief from their symptoms after using kratom products. An associate professor of psychiatry who studied kratom users described it as a potentially helpful analgesic that, for many respondents, eased discomfort without the heavy sedation often associated with traditional opioid medications, allowing them to continue working and engaging with daily life.
Kratom’s appeal is not limited to pain. A number of people report using it as part of their efforts to reduce or discontinue other substances, particularly prescription or illicit opioids. In the user survey highlighted by Live Science, many participants said kratom helped them soften the impact of withdrawal symptoms and cravings, and some reported that it played a role in their ability to stop using opioids entirely. The National Institute on Drug Abuse notes on its kratom page that some individuals describe using kratom in this way, while emphasizing that the plant is not an approved treatment for opioid use disorder and that formal clinical trials are still needed to clarify its role in this context, a point that can be explored further in NIDA’s online discussion of kratom’s potential therapeutic and safety profile.
Others say kratom supports their mental well-being. In the same survey, participants described using it to ease social anxiety and symptoms related to post-traumatic stress, often seeking a calmer or more stable emotional state. A 2022 article, “Understanding Kratom Use: A Guide for Healthcare Providers,” published in Frontiers in Pharmacology and available through Frontiers in Pharmacology, reports that many Western kratom users similarly cite improvements in mood, reduced anxiety and better ability to cope with stress as reasons for their use, while the authors carefully note that these are self-reported experiences rather than outcomes from large, controlled studies.
From a scientific perspective, kratom occupies a somewhat unique space. Researchers agree that its effects are largely driven by naturally occurring alkaloids, particularly mitragynine and 7-hydroxymitragynine, which interact with opioid receptors in the brain, as summarized in a 2024 review on kratom pharmacology available via PubMed Central. In the Live Science feature, researcher Marc Swogger summarized the pharmacology by saying that kratom is “not an opiate, but it binds to the opiate receptor,” a description that captures its opioid-like mechanism without placing it in exactly the same category as traditional opioid drugs. A systematic review of toxicological issues in kratom published in Wiley Interdisciplinary Reviews likewise notes that the plant contains dozens of alkaloids, with mitragynine and 7-hydroxymitragynine receiving particular attention for both possible benefits and safety considerations, a discussion that readers can find in more detail at Wiley.
One of the characteristics that users and scientists both find noteworthy is kratom’s dose-dependent profile. Many people say that lower servings feel gently stimulating, somewhat reminiscent of strong coffee, while higher amounts are described as more relaxing and, for some, moderately sedating. In user reports compiled in the Live Science article, people frequently said they could achieve pain relief and improved comfort while still feeling able to carry out normal daytime activities, especially at lower or moderate doses, which they contrasted with the more pronounced sedation of some prescription medications. The NIDA overview similarly explains that kratom may produce stimulant-like effects at low doses and more opioid-like effects at higher doses, reflecting this nuanced dose–response relationship.
Because kratom is now sold worldwide in a variety of forms and potencies, regulators focus much of their attention on ensuring that consumers have clear, accurate information. The DEA’s publicly available “Drug Fact Sheet: Kratom” identifies it as a substance of concern, primarily because its main alkaloids act at opioid receptors and because products can vary significantly in composition. For its part, the FDA underscores on its “FDA and Kratom” page that no kratom product has been approved for treating any medical condition, and the agency has issued public communications advising consumers and healthcare professionals that kratom should be approached thoughtfully, especially when other medications or health conditions are involved.
In studies of people who use kratom regularly, side effects are part of the picture but are often described in relatively manageable terms. The research summarized by Live Science found that common unwanted effects reported by users included nausea, vomiting, itching and mild sedation, symptoms that participants usually viewed as tolerable or comparable to those associated with other everyday substances. Reviews from NIDA and other scientific sources note that, while more serious reactions have been documented in some case reports, these events appear to be uncommon relative to overall use and are often associated with factors such as very high doses, combinations with other substances or underlying health issues, which reinforces the value of moderation and medical guidance where appropriate, as detailed in the clinical literature and in public information from agencies such as NIDA.
Researchers have also identified a small number of cases in which kratom use coincided with liver problems. The user survey highlighted in Live Science referred to two such reports and concluded that, given the limited controlled human data available, the long-term safety of frequent, high-dose kratom consumption has not yet been firmly established. The FDA includes liver injury among the potential risks it monitors in relation to kratom and encourages healthcare professionals to ask about kratom use when evaluating unexplained liver concerns, viewing this as part of routine, careful clinical practice rather than as a judgment on any individual’s choice to use the plant, as reflected in its guidance on the “FDA and Kratom” page.
Questions about dependence and withdrawal are treated in a similarly measured way in the scientific and regulatory literature. The DEA notes in its fact sheet that, because kratom’s main alkaloids act on opioid receptors, some people who use kratom heavily can develop patterns of use that are difficult to change, and may experience withdrawal-like symptoms if they suddenly stop. In the survey of users described by Live Science, about one in ten respondents who reported heavy, regular use said they experienced symptoms such as irritability, cravings or physical discomfort after a period without kratom, although most characterized these experiences as milder than those associated with traditional opioids. NIDA’s overview echoes this, explaining that people can become dependent on kratom and that any decision about long-term use or tapering is best made in partnership with a healthcare professional, a point the institute highlights as part of a broader harm-reduction and patient-centered approach.
For individuals with a history of substance use challenges, researchers recommend a particularly thoughtful approach. The authors of the study featured by Live Science stressed that these individuals should carefully weigh the potential advantages—such as relief from pain or support during efforts to reduce other drugs—against the possibility that kratom itself may become a regular habit that can be hard to change. This is consistent with broader guidance from organizations like NIDA, which encourages open, non-stigmatizing conversations between patients and clinicians about any substances being used, including kratom, so that care decisions can be made with a full picture of potential interactions and goals, an approach described extensively on NIDA’s treatment and recovery pages.
The policy landscape reflects this call for balance. Agencies such as the FDA and DEA emphasize product quality, labeling accuracy and consumer education, and they have raised concerns about synthetic or highly concentrated kratom-derived products, such as isolated 7-hydroxymitragynine, which can behave differently from traditional preparations; the FDA, for example, has discussed scheduling recommendations for certain synthetic kratom compounds in its public regulatory updates, and background on these deliberations can be found through both FDA notices and independent regulatory analyses at sites like the Food Research Lab. At the same time, millions of users and some scientists highlight kratom’s potential as a plant-based option that may help certain people manage pain or reduce reliance on more potent substances, arguing that well-crafted regulations and clearer standards could support safer access rather than eliminating it, a perspective also discussed in academic and policy papers such as “Understanding Kratom Use: A Guide for Healthcare Providers.”
What is clear is that kratom continues to evolve from a local traditional remedy into a global product under active study. Federal research agencies such as NIDA are supporting investigations into how kratom’s alkaloids work in the body, how different doses affect pain and mood, and how best to guide consumers toward informed choices, as detailed in ongoing research updates on the NIDA kratom page and related scientific publications. As those studies progress, the public conversation is likely to move beyond simple “for or against” narratives, toward a more nuanced view of kratom as a complex botanical that, like many such substances, offers both possibilities and responsibilities for the people who choose to use it.